download
FREE KOL List
    • KOL
    • KOLs Community
    • Fecal
    • Fecal Microbiota
    • Fecal Microbiota Transplantation
    • Lawrence J Brandt
    • Lawrence J Brandt

      Lawrence J Brandt

      Department of Medicine, Montefiore Medical Center, Bronx, NY USA | Albert Einstein College of Medicine, Bronx, NY USA | Division of Gastroenterology, Montefiore Medical ...

       

       

      KOL Resume for Lawrence J Brandt

      Year
      2021

      Department of Medicine, Montefiore Medical Center, Bronx, NY USA

      2019

      Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

      Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA.

      2018

      Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

      2017

      From the Albert Einstein College of Medicine, NY.

      Division of Gastroenterology and Liver Diseases, Montefiore Medical Center/Albert Einstein College of Medicine

      2016

      Department of Medicine, Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA

      From Warren Alpert Medical School of Brown University, Miriam Hospital, and Lifespan Hospital System, Providence, Rhode Island; University of Minnesota, Minneapolis/St. Paul, Minnesota; Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York; and University of Rhode Island, Kingston, Rhode Island.

      2015

      Division of Gastroenterology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

      2014

      Dr Aroniadis is a gastroenterology fellow at Montefiore Medical Center in the Bronx, New York. Dr Brandt is the emeritus chief of gastroenterology at Montefiore Medical Center and a professor of medicine and surgery at the Albert Einstein College of Medicine of Yeshiva University in the Bronx, New York.

      Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA

      2013

      Montefiore Medical Center, Bronx, New York, USA.

      Division of Gastroenterology

      2012

      Division of Gastroenterology, Montefiore Medical Center, Albert Einstein School of Medicine, Bronx, New York

      2011

      Montefiore Medical Center, Bronx, NY, USA.

      Division of Gastroenterology, Department of Medicine, Bronx, NY

      2010

      Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY

      Division of Gastroenterology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York, USA

      William O. Tschumy Jr., MD, Chair of Internal Medicine, Director, Internal Medicine Residency Program, Medical Director, Research Services, Texas Health Presbyterian Hospital Dallas, Clinical Professor of Internal Medicine, University of Texas Southwestern Medical School, Dallas, Texas

      2008

      Gastroenterology, Montefiore Medical Center, Bronx, New York, USA

      Montefiore Medical Center/ Albert Einstein College of Medicine, Bronx, New York

      2007

      Albert Einstein College of Medicine, Moses Division of Montefiore Medical Center, Department of Medicine, Division of Gastroenterology, Bronx, New York

      2005

      Division of Gastroenterology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA

      2004

      Montefiore Medical Center Bronx, New York USA

      2003

      Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, 10467, Bronx, NY, USA

      2002

      Chapel Hill, North Carolina, and Bronx, New York

      Albert Einstein College of Medicine, Bronx, NY, USA.

      2001

      and Montefiore Medical Center (LJB), Bronx, New York

      Division of Gastroenterology, Department of Medicine, Albert Einstein College of Medicine (PKS-N, LJB)

      2000

      Division of Gastroenterology, Montefiore Medical Center, The Albert Einstein College of Medicine, Bronx, New York, USA

      Montefiore Medical Center/Albert Einstein, College of Medicine, Bronx, New York

      1999

      Division of Gastroenterology and Nutrition, Department of Pediatrics; †Division of Gastroenterology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.

      Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York USA

      1998

      Division of Gastroenterology, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA

      1997

      Medicine–Gastroenterology (LJB), Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York

      1996

      Division of Gastroenterology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Am J Gastroenterol 1995;90:1918-1922

      1995

      University of Medicine and Dentistry of New Jersey, Stratford, New Jersey, USA

      Montefiore Hospital Bronx, New York

      1994

      Division of Gastroenterology, Department of Medicine, Montefiore Medical Center and the Albert Einstein College of Medicine, Bronx, New York

      1993

      Division of Gastroenterology, Albert Einstein College of Medicine, Bronx Municipal Hospital Center, and Montefiore Hospital Center, Bronx, New York, USA

      Departments of Medicine-Gastroenterology and Pathology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York

      1992

      Department of Medicine, Division of Gastroenterology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York

      1991

      Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York 10467.

      1990

      Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467

      1989

      Department of Medicine, Division of Gastroenterology, Department of Pathology, Montefiore Medical Center of the Albert Einstein College of Medicine, Bronx, New York

      1988

      Department of Medicine, Division of Gastroenterotogy, Montefiore Medical Center/Albert Einstein College of Medicine, and Department of Pathology, Albert Einstein College of Medicine, Bronx, New York

      1987

      Department of Medicine Division of Gastroenterology Montefiore Medical Center 111 East 210th Street Bronx, New York 10467

      Bronx, New York, USA

       

       

      Lawrence J Brandt: Influence Statistics

      Sample of concepts for which Lawrence J Brandt is among the top experts in the world.
      Concept World rank
      questionably viable bowel #1
      enterocolitis physician attitudes #1
      therapeutic potential fmt #1
      95 peritoneal signs #1
      secondary cure rate #1
      female humans enterocolitis #1
      ectasias diverticulosis common #1
      middle aged pneumatosis #1
      3 recurrences #1
      management mesenteric ischemia #1
      90 fmt #1
      disease male specimen #1
      intestinalis complicating #1
      recurrent barretts epithelium #1
      presentday attempts #1
      variety aids #1
      conservative supportive therapy #1
      cohorts cdi #1
      fmt step #1
      rcdi future #1
      vascular ectasias ectasias #1
      favorable outcome ibd #1
      rifaximin chronic #1
      gastrointestinal microbiota gimb #1
      paper unrecognized #1
      08 cdi #1
      duodenum endoscopy congo #1
      intestines metagenome transplantation #1
      elderly patients clostridioides #1
      ischemia nasal #1
      rates repeat infection #1
      lifes valuable axioms #1
      diverticulosis classified #1
      cdi assay cdi #1
      stricture gangrene #1
      illness fmt #1
      colonoscopic evidence cdi #1
      ibs controlled #1
      aggressive medical gastric #1

       

      Prominent publications by Lawrence J Brandt

      KOL-Index: 18454

      OBJECTIVES: Patients who are immunocompromised (IC) are at increased risk of Clostridium difficile infection (CDI), which has increased to epidemic proportions over the past decade. Fecal microbiota transplantation (FMT) appears effective for the treatment of CDI, although there is concern that IC patients may be at increased risk of having adverse events (AEs) related to FMT. This study describes the multicenter experience of FMT in IC patients.

      METHODS: A multicenter retrospective ...

      Known for Fmt Patients | Treatment Cdi | Microbiota Transplant | 12 Weeks | Clostridium Difficile Infection
      KOL-Index: 15226

      OBJECTIVES: Clostridium difficile infection (CDI) has increased to epidemic proportions over the past 15 years, and recurrence rates of 30-65% with failure to respond to multiple courses of antimicrobials are common. The aim of this study was to report the efficacy of fecal microbiota transplantation (FMT) in patients with recurrent CDI in five geographically disparate medical centers across the United States.

      METHODS: A multicenter long-term follow-up study was performed on the use of ...

      Known for Fmt Patients | Recurrent Cdi | United States | Colonoscopy Enterocolitis | Resolution Diarrhea
      KOL-Index: 13609

      OBJECTIVES: Over the past decade, the epidemiology of Clostridium difficile infection (CDI) has shown a remarkable increase in incidence with an associated increase in severity. This study was designed to compare the demographics, medication exposure, evaluation, treatment patterns, and outcomes of patients with CDI in two different time periods: 2006-2008 and 2009-2011. We hypothesized that mortality is decreasing with increasing appropriateness of medical management.

      METHODS: We ...

      Known for Patients Cdi | Difficile Infection | Metronidazole Vancomycin | 30day Mortality | Anti Bacterial
      KOL-Index: 12115

      OBJECTIVES: Clostridium difficile infection (CDI) in the elderly has a higher prevalence, greater morbidity and mortality, and lower response to conventional treatment than the general population. Fecal microbiota transplant (FMT) is highly effective therapy for CDI but has not been studied specifically in the elderly. This study aims to determine the long-term efficacy and safety of FMT for recurrent (RCDI), severe (SCDI), and complicated (CCDI) CDI in elderly patients.

      METHODS: A ...

      Known for Microbiota Transplant | Clostridium Difficile | Fmt Rcdi | Elderly Patients | Term Efficacy
      KOL-Index: 10637

      Bacterial communities from subjects treated for recurrent Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT), using either heterologous donor stool samples or autologous stool samples, were characterized by Illumina next-generation sequencing. As previously reported, the success of heterologous FMT (90%) was superior to that of autologous FMT (43%) (P = 0.019), and post-FMT intestinal bacterial communities differed significantly between treatment arms (P < ...

      Known for Fecal Microbiota Transplantation | Clostridium Difficile | Microbiota Engraftment | Bacterial Communities | Fmt Samples
      KOL-Index: 10538

      Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label clinical trials.

      Objective: To determine the efficacy and safety of FMT for treatment of recurrent CDI.

      Design: Randomized, controlled, double-blind clinical trial. (ClinicalTrials.gov: NCT01703494).

      Setting: Two academic medical centers.

      Patients: 46 patients who had 3 or more recurrences of CDI and ...

      Known for Fecal Microbiota Transplantation | Autologous Fmt | Donor Stool | Recurrent Cdi | Clostridium Difficile
      KOL-Index: 10295

      GOAL: Our aim was to investigate fecal microbiota transplantation (FMT) efficacy in patients with severe and/or complicated Clostridium difficile infection (CDI).

      BACKGROUND: FMT is successful for recurrent CDI, although its benefit in severe or complicated CDI has not specifically been evaluated.

      STUDY METHODS: A multicenter long-term follow-up study was performed in patients who received FMT for severe and/or complicated CDI (diagnosed using standard criteria). Pre-FMT and post-FMT ...

      Known for Complicated Clostridium | Fmt Patients | Fecal Microbiota | Difficile Infection | Cure Rates
      KOL-Index: 10251

      BACKGROUND: In general, ischemic colitis has a very good prognosis, but there is concern that when ischemia affects the right side of the colon in an isolated fashion, the prognosis may not be so favorable.

      OBJECTIVE: The aim of this study was to compare the clinical features and outcomes of ischemia isolated to the right side of the colon with those of ischemia involving other areas of the colon.

      METHODS: A retrospective study was undertaken of patients with colon ischemia hospitalized ...

      Known for Ischemic Colitis | Colon Ischemia | Worse Prognosis | Retrospective Study Patients | Icd9 Codes
      KOL-Index: 9935

      OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic functional disorder. 5-Hydroxytryptamine (5-HT) is a key modulator of gastrointestinal sensorimotor function. Many patients have IBS that can be difficult to treat, which has led to the development of newer agents, such as 5-HT(3) antagonists and 5-HT(4) agonists. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to estimate the efficacy of all available 5-HT agents in IBS.

      METHODS: MEDLINE, ...

      Known for Irritable Bowel Syndrome | 5ht3 Antagonists | Tegaserod Placebo | Systematic Review Metaanalysis | Ibs Alosetron
      KOL-Index: 9405

      BACKGROUND: Faecal microbiota transplantation (FMT) has shown promise in alleviating the symptoms of irritable bowel syndrome (IBS); however, controlled data on this technique are scarce. The aim of this clinical trial was to assess the efficacy of FMT in alleviating diarrhoea-predominant IBS (IBS-D).

      METHODS: We did a double-blind, randomised, placebo-controlled crossover trial in patients aged 18-65 years with moderate-to-severe IBS-D defined by an IBS-Symptom Severity Score (IBS-SSS) ...

      Known for Microbiota Transplantation | Irritable Bowel | 12 Weeks | Fmt Capsules | Controlled Trial
      KOL-Index: 9075

      OBJECTIVES: Previous reports on the anatomic portions of colon involved in cases of supposed ischemic colitis (IC) have been limited by the absence of confirmation of the true nature of the disease. This is the first anatomic study to define the patterns of colon involvement in which only cases with biopsy-proven or -compatible IC and in which the entire colon had been visualized at surgery or at colonoscopy were included. The aims of this study were to re-examine patterns of colonic ...

      Known for Patient Characteristics | Colon Involvement | Colitis Ischemic | Surgery Mortality | Severity Disease
      KOL-Index: 8935

      BACKGROUND: Clostridium difficile infection (CDI) is the most common nosocomial infection in the US and cirrhotic patients with CDI have increased risk for poor outcome.

      AIM: The aim of this study is to evaluate the impact of CDI on short-term mortality in patients with cirrhosis and identify predictors of mortality in these patients.

      METHODS: We retrospectively identified patients at Montefiore Medical Center from 2010 to 2014 with cirrhosis, diarrhea and a C. difficile toxin assay. ...

      Known for Difficile Infection | Cirrhotic Patients | Cirrhosis Cdi | 30day Mortality | Liver Disease
      KOL-Index: 8444

      INTRODUCTION: Probiotics may benefit irritable bowel syndrome (IBS) symptoms, but randomised controlled trials (RCTs) have been conflicting; therefore a systematic review was conducted.

      METHODS: MEDLINE (1966 to May 2008), EMBASE (1988 to May 2008) and the Cochrane Controlled Trials Register (2008) electronic databases were searched, as were abstracts from DDW (Digestive Diseases Week) and UEGW (United European Gastroenterology Week), and authors were contacted for extra information. ...

      Known for Probiotics Treatment | Irritable Bowel | Placebo Ibs | Continuous Data | Trials Rcts

      Key People For Fecal Microbiota Transplantation

      Top KOLs in the world
      #1
      Willem Meindert de Vos
      intestinal microbiota lactococcus lactis lactic acid bacteria
      #2
      Max Nieuwdorp
      gut microbiota type 2 diabetes metabolic syndrome
      #3
      Alexander Khoruts
      fecal microbiota transplantation gut microbiota difficile infection
      #4
      Thomas Julius Borody
      fecal microbiota transplantation helicobacter pylori ulcerative colitis
      #5
      Colleen R Kelly
      fecal microbiota transplantation difficile infection fmt patients
      #6
      Erwin Gerard Zoetendal
      gut microbiota african americans breast milk
      Select a search phrase   fecal microbiota transplantation

      Lawrence J Brandt:Expert Impact

      Concepts for whichLawrence J Brandthas direct influence:Fecal microbiota transplantation,  Colon ischemia,  Infectious diarrhea,  Chronic rifaximin,  Flexible sigmoidoscopy,  Vascular ectasias,  Difficile infection,  Colonic ischemia.

      Lawrence J Brandt:KOL impact

      Concepts related to the work of other authors for whichfor which Lawrence J Brandt has influence:Irritable bowel syndrome,  Gut microbiota,  Clostridium difficile,  Inflammatory bowel disease,  Ischemic colitis,  Mesenteric ischemia,  Abdominal pain.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Medicine, Montefiore Medical Center, Bronx, NY USA | Albert Einstein College of Medicine, Bronx, NY USA | Division of Gastroenterology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467 USA | Division of Gastroenterology

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.